Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27106377 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL27108569 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL24540367 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL23555453 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL141264 | 0.91 | NR1H2 (0.36) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL15632355 | 0.91 | NR1H2 (0.36) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL1882303 | 0.91 | NR1H2 (0.36) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL573307 | 0.91 | NR1H2 (0.36) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL9595376 | 0.91 | NR1H2 (0.36) | ALDH1A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL31234239 | 0.91 | NR1H2 (0.36) | ALDH1A1CHRM2CHRM1CHRM3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | ALDH1A1 3005/4885CHRM2 2317/4885CHRM1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.